IBRX
ImmunityBio, Inc.Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted net loss attributable to ImmunityBio common stockholders non-GAAP | $86.2M | Q1 2026 | — |
| ANKTIVA Unit Growth | 168% | Q1 2026 | — |
| countries represented by regulatory approvals or authorizations of ANKTIVA | 34 | Q1 2026 | — |
| ANKTIVA unit sales volume growth | 750% | FY 2025 compared to 2024 | — |
| quarter over quarter unit volume growth rate | 54% | FY 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IBRX
this stock
ImmunityBio, Inc.
|
$9.29B | +344.4% | +668.3% | — | 12.9% |
|
ONC
BeOne Medicines Ltd.
|
$437.67B | -0.6% | +22179.2% | 890.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.03B | -14.0% | +20.8% | 16.3 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IBRX | +0.5% | +22.7% | +212.1% | +0.5% | +344.4% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +0.7% | +21.9% | +204.6% | +0.7% | +335.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.